These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16158128)

  • 1. Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients.
    Vishweshwar P; McMahon JA; Peterson ML; Hickey MB; Shattock TR; Zaworotko MJ
    Chem Commun (Camb); 2005 Sep; (36):4601-3. PubMed ID: 16158128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amide-N-oxide heterosynthon and amide dimer homosynthon in cocrystals of carboxamide drugs and pyridine N-oxides.
    Babu NJ; Reddy LS; Nangia A
    Mol Pharm; 2007; 4(3):417-34. PubMed ID: 17497888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hierarchy of supramolecular synthons: persistent hydroxyl...pyridine hydrogen bonds in cocrystals that contain a cyano acceptor.
    Bis JA; Vishweshwar P; Weyna D; Zaworotko MJ
    Mol Pharm; 2007; 4(3):401-16. PubMed ID: 17500564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of the use of powder X-ray diffraction, Raman and near infrared spectroscopy for quantification of binary polymorphic mixtures of piracetam.
    Croker DM; Hennigan MC; Maher A; Hu Y; Ryder AG; Hodnett BK
    J Pharm Biomed Anal; 2012 Apr; 63():80-6. PubMed ID: 22333478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?
    Almarsson O; Zaworotko MJ
    Chem Commun (Camb); 2004 Sep; (17):1889-96. PubMed ID: 15340589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-crystals of caffeine and hydroxy-2-naphthoic acids: unusual formation of the carboxylic acid dimer in the presence of a heterosynthon.
    Bucar DK; Henry RF; Lou X; Duerst RW; Borchardt TB; MacGillivray LR; Zhang GG
    Mol Pharm; 2007; 4(3):339-46. PubMed ID: 17489605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supercritical carbon dioxide processing of active pharmaceutical ingredients for polymorphic control and for complex formation.
    Moribe K; Tozuka Y; Yamamoto K
    Adv Drug Deliv Rev; 2008 Feb; 60(3):328-38. PubMed ID: 18006109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal engineering of pharmaceutical Co-crystals: application of methyl paraben as molecular hook.
    Khan M; Enkelmann V; Brunklaus G
    J Am Chem Soc; 2010 Apr; 132(14):5254-63. PubMed ID: 20235531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical co-crystals.
    Vishweshwar P; McMahon JA; Bis JA; Zaworotko MJ
    J Pharm Sci; 2006 Mar; 95(3):499-516. PubMed ID: 16444755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chiral carboxylic acids and their effects on melting-point behaviour in co-crystals with isonicotinamide.
    Lemmerer A; Báthori NB; Bourne SA
    Acta Crystallogr B; 2008 Dec; 64(Pt 6):780-90. PubMed ID: 19029707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solid-state interactions of calixarenes with biorelevant molecules.
    Danylyuk O; Suwinska K
    Chem Commun (Camb); 2009 Oct; (39):5799-813. PubMed ID: 19787105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding the scope of crystal form evaluation in pharmaceutical science.
    Peterson ML; Hickey MB; Zaworotko MJ; Almarsson O
    J Pharm Pharm Sci; 2006; 9(3):317-26. PubMed ID: 17207415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining piracetam and lithium salts: ionic co-crystals and co-drugs?
    Braga D; Grepioni F; Maini L; Capucci D; Nanna S; Wouters J; Aerts L; Quéré L
    Chem Commun (Camb); 2012 Aug; 48(66):8219-21. PubMed ID: 22781963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binary co-crystals of the active pharmaceutical ingredient 1,4-bis(4-pyridyl)-2,3-diaza-1,3-butadiene and camphoric acid.
    Bisht KK; Patel P; Rachuri Y; Eringathodi S
    Acta Crystallogr B Struct Sci Cryst Eng Mater; 2014 Feb; 70(Pt 1):63-71. PubMed ID: 24441129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
    Blagden N; de Matas M; Gavan PT; York P
    Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-pyrrolidinone moiety is not critical for the cognition-enhancing activity of piracetam-like drugs.
    Scapecchi S; Martelli C; Ghelardini C; Guandalini L; Martini E; Gualtieri F
    Farmaco; 2003 Sep; 58(9):715-22. PubMed ID: 13679165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of position isomerism on the formation and physicochemical properties of pharmaceutical co-crystals.
    Liao X; Gautam M; Grill A; Zhu HJ
    J Pharm Sci; 2010 Jan; 99(1):246-54. PubMed ID: 19504586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solvent influences on metastable polymorph lifetimes: real-time interconversions using energy dispersive X-ray diffractometry.
    DeMatos LL; Williams AC; Booth SW; Petts CR; Taylor DJ; Blagden N
    J Pharm Sci; 2007 May; 96(5):1069-78. PubMed ID: 17455330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Environmental effects on charge densities of biologically active molecules: do molecule crystal environments indeed approximate protein surroundings?
    Mladenovic M; Arnone M; Fink RF; Engels B
    J Phys Chem B; 2009 Apr; 113(15):5072-82. PubMed ID: 19320453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboxamide-pyridine N-oxide heterosynthon for crystal engineering and pharmaceutical cocrystals.
    Reddy LS; Babu NJ; Nangia A
    Chem Commun (Camb); 2006 Apr; (13):1369-71. PubMed ID: 16550269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.